New Target Identified to Combat Coronavirus Spread

Researchers at Pompeu Fabra University in Barcelona have identified a key mechanism used by coronaviruses to rapidly spread within cells, offering a potential new therapeutic target for broad-spectrum antiviral drugs. The study, published in Nature Communications, reveals that coronaviruses manipulate cellular machinery to optimize conditions for viral protein production.

How Coronaviruses Hijack Cellular Processes

Coronaviruses, like all viruses, rely on host cell machinery to replicate. A crucial part of this process involves transfer RNAs (tRNAs), which deliver amino acids to build new proteins based on genetic instructions. The research team discovered that coronaviruses activate enzymes that modify these tRNAs, essentially reprogramming the cell to favor viral protein production.

“Coronaviruses need tRNAs that are in low concentrations in cells,” explains Elena Muscolino, first author of the study. “For this reason we asked ourselves how a virus can spread so quickly within a cell where the tRNAs it needs to make its viral proteins are not abundant.”

The Role of Cellular Stress Response

The study found that viral infection triggers a cellular stress response, chemically altering tRNAs and changing how the cell functions. This shift creates an environment ideal for the virus to thrive. Specifically, the cell begins producing proteins designed to combat stress, and, crucially, these proteins require the same tRNAs needed by the coronavirus to manufacture its own viral proteins.

“In order to manufacture stress response proteins, the same tRNAs that coronaviruses need to manufacture their viral proteins are needed,” explains Mireia Puig, a co-author of the work.

A Common Strategy Among Coronaviruses

The modification of tRNAs was observed in both SARS-CoV-2, the virus responsible for the COVID-19 pandemic and HCoV-OC43, a coronavirus that typically causes mild cold-like symptoms. This suggests that tRNA modification may be a common strategy employed by different coronaviruses to enhance their spread. Blocking the activity of these tRNA-modifying enzymes significantly reduced viral protein production in laboratory settings.

Implications for Antiviral Drug Development

“The tRNA-modifying enzyme is a promising candidate for developing broad-spectrum antiviral drugs capable of curbing the spread of coronaviruses,” states Juana Díez, director of the Molecular Virology Research Group at Pompeu Fabra University, who led the research. “A drug of this type would allow us to contain the infections caused by new coronaviruses from their initial phases and prevent their rapid expansion, and new pandemics.”

The need for such drugs is pressing, as the scientific community widely anticipates the emergence of new coronaviruses. Currently, there are no broadly effective antiviral treatments available, leaving the world vulnerable to future outbreaks. As Juana Díez explains, “Coronaviruses are highly dangerous because of their ability to generate new variants capable of infecting humans after circulating in animal reservoirs.”

Looking Ahead

This research provides a crucial step forward in understanding how coronaviruses exploit cellular processes and identifies a promising target for the development of new antiviral therapies. Further research will focus on developing drugs that specifically inhibit the tRNA-modifying enzymes, potentially offering a powerful tool to combat current and future coronavirus threats.